May 2026 Medtronic expanded its deep brain stimulation portfolio with next-generation adaptive DBS technologies featuring AI-enabled programming and personalized stimulation to improve outcomes for patients with movement disorders.
March 2026 Abbott introduced advanced deep brain stimulation systems with enhanced directional leads, expanded MRI compatibility, and improved clinician programming tools for neurological disorder management.
October 2025 Boston Scientific expanded its Vercise™ DBS portfolio with upgraded software and remote programming capabilities, enabling more personalized therapy for patients with Parkinson’s disease and essential tremor.
June 2025 NeuroPace advanced its neuromodulation portfolio by expanding clinical research into next-generation brain stimulation technologies for the treatment of epilepsy and other neurological disorders.